Michael Tong News
-
China may sign the first foreign orders for its CAP1400 nuclear reactor this year, the China Daily reported today, citing Sun Qin, chairman of the nation’s largest atomic plant builder.
-
Zogenix Inc., the drugmaker seeking to bring the first pure hydrocodone painkiller to market, rose the most ever on increased investor expectations of U.S. regulatory approval.
-
Xinjiang Goldwind Science & Technology Co. advanced the most in almost 16 months in Hong Kong after Deutsche Bank AG recommended buying China’s largest maker of wind turbines as capacity and orders are seen rising.
-
China Longyuan Power Group and Xinjiang Goldwind Science & Technology Co. surged in Asian trading after Deutsche Bank AG began coverage with ‘buy” ratings and China overtook the U.S. as the biggest energy user.
-
Columbia Laboratories Inc. fell the most in almost five years after a panel advising U.S. regulators didn’t back the company’s gel to prevent preterm births.
-
Columbia Laboratories Inc. and Watson Pharmaceuticals Inc. failed to win the backing of advisers to U.S. regulators for the companies’ progesterone gel to prevent preterm birth. Shares of Columbia Labs fell as much as 67 percent in extended trading.
-
China, the world’s fastest-growing major economy, may face a summer power shortage of 30 million kilowatts as supply lags behind demand growth, the China Electricity Council said.
-
Watson Pharmaceuticals Inc., the second-biggest U.S. generic-drug maker, failed to win approval for its progesterone gel to prevent preterm birth.
-
Chinese shares traded in New York rose as Huaneng Power International Inc., the nation’s biggest power producer, jumped after Deutsche Bank AG raised the stock to “buy” and as concern waned that Europe’s debt crisis is deepening.
-
Arsenal rallied from a 4-0 first- half deficit to beat Reading 7-5 after extra time on a night of upsets in the fourth round of English soccer’s League Cup.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page